ArticleFrontiers in immunology2021
Using Routine Laboratory Markers and Immunological Indicators for Predicting
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Advances in pathogen detection ofInfectious medicine · 2025Review
- Pneumocystis jirovecii pneumonia in a patient with Mycobacterium intracellulare pulmonary disease: a case report.BMC infectious diseases · 2025Article
- Clinical analysis of Pneumocystis jirovecii pneumonia in children with malignant disease.BMC pediatrics · 2025Article
- Clinical characteristics ofJournal of thoracic disease · 2025Article
- Development of a prediction model for in-hospital mortality in immunocompromised chronic kidney diseases patients with severe infection.BMC nephrology · 2025Article
- A case report of AIDS complicated byFrontiers in medicine · 2025Article
- T-cell subsets inClinical & translational immunology · 2025Review
- A combined immune and inflammatory indicator predict the prognosis of severe Pneumocystis jirovecii pneumonia patients: a 12-year, retrospective, observational cohort.BMC pulmonary medicine · 2024Observational
- Circulating TIGITHeliyon · 2024Article
- Alterations of lung microbiota in lung transplant recipients with pneumocystis jirovecii pneumonia.Respiratory research · 2024Observational
- Decreased expression of NAT10 in peripheral blood mononuclear cells from new-onset ankylosing spondylitis and its clinical significance.Arthritis research & therapy · 2024Article
- Clinical course and prognostic factors ofFrontiers in cellular and infection microbiology · 2024Article
- Study on mNGS Technique in DiagnosingInfection and drug resistance · 2024Article
- Relationship between clinical features and droplet digital PCR copy number in non-HIV patients with pneumocystis pneumonia.BMC infectious diseases · 2023Article
- Negative serum (1,3) -β-D-glucan has a low power to exclude Pneumocystis jirovecii pneumonia (PJP) in HIV-uninfected patients with positive qPCR.Annals of clinical microbiology and antimicrobials · 2023Article
- Machine Learning Models for Prediction of SevereDiagnostics (Basel, Switzerland) · 2023Article
- Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing.BMC pulmonary medicine · 2023Article
- Metagenomic next-generation sequencing for the diagnosis of Pneumocystis jirovecii Pneumonia in critically pediatric patients.Annals of clinical microbiology and antimicrobials · 2023Article
- Development and Validation of a Diagnostic Nomogram forInfection and drug resistance · 2023Article
- Development and validation of tools for predicting the risk of death and ICU admission of non-HIV-infected patients withFrontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pneumocystis jiroveci pneumonia (PJP) is the most common opportunistic infection in immunocompromised patients. The accurate prediction of PJP development in patients undergoing immunosuppressive therapy remains challenge. Methods: Patients undergoing immunosuppressive treatment and with confirmed pneumocystis jiroveci infection were enrolled. Another group of matched patients with immunosuppressant treatment but without signs of infectious diseases were enrolled to control group. Results: A total of 80 (40 PJP, 40 non-PJP) participants were enrolled from Tongji Hospital. None of the patients were HIV positive. The routine laboratory indicators, such as LYM, MON, RBC, TP, and ALB, were significantly lower in PJP patients than in non-PJP patients. Conversely, LDH in PJP patients was significantly higher than in non-PJP controls. For immunological indicators, the numbers of T, B, and NK cells were all remarkably lower in PJP patients than in non-PJP controls, whereas the functional markers such as HLA-DR, CD45RO and CD28 expressed on CD4 Conclusions: A model based on combination of routine laboratory and immunological indicators shows prominent value for predicting the development of PJP in HIV-negative patients undergoing immunosuppressive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.